LUCINDA FAN: Open Payments
NPI 1578232534 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,242 in 130 payments from 18 companies in 2025. Trend: 2023 $1,716 · 2024 $1,757 · 2025 $3,242
Food & beverage: $3,158Education: $84
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 17 | $468 |
| ABBVIE INC. | 25 | $467 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $407 |
| Madrigal Pharmaceuticals | 13 | $405 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $309 |
| GENZYME CORPORATION | 6 | $258 |
| Celltrion USA Inc. | 9 | $194 |
| Lilly USA, LLC | 5 | $148 |
| PFIZER INC. | 7 | $129 |
| Regeneron Healthcare Solutions, Inc. | 4 | $116 |
Products named: TREMFYA, REZDIFFRA, DUPIXENT, XIFAXAN, ENTYVIO, VEGZELMA, RINVOQ, LINZESS.
Industry payments across CA — which companies pay providers there.
